Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.1c02175
Abstract: The transcriptional repressor BCL6 is an oncogenic driver found to be deregulated in lymphoid malignancies. Herein, we report the optimization of our previously reported benzimidazolone molecular glue-type degrader CCT369260 to CCT373566, a highly potent probe… read more here.
Keywords: bcl6 vivo; vivo; improved binding; bcl6 ... See more keywords